Interleukin 2 (IL-2) is the only systemic treatment currently ... who develop progressive disease after cytokine therapy”. In the commentary of the paper on sunitinib, however, Stadler and ...

from the Utrecht Medical Centre in The Netherlands provides the first clinical evidence, to the authors' knowledge, that local interleukin-2 (IL-2) therapy in combination with radiotherapy is an ...

The drug, SAR444245, is part of an emerging class of cancer immunotherapies based on interleukin-2 (IL-2 ... Use of the one FDA-approved IL-2 therapy is limited by its toxicity.

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

MedStar Georgetown University Hospital is the first hospital in the Washington metropolitan area to offer Tumor-Infiltrating ...